Zim Laboratories reported a widened consolidated net loss of ₹401.70 lakh for the quarter ended June 30, 2026 (Q1FY27), compared to a net loss of ₹187.49 lakh in the corresponding period last year. Despite the bottom-line deterioration, consolidated revenue from operations grew significantly by 31.2% year-on-year to ₹9,417.85 lakh, up from ₹7,175.61 lakh in Q1FY25. The divergence between top-line growth and bottom-line decline signals ongoing margin compression within its pharmaceutical segment, driven by rising operational expenses that outpaced sales volume increases.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 06, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells LLP, the statutory auditors, issued a limited review report on the interim financial statements, confirming no material misstatements were observed. The results were published in Financial Express, Indian Express, and Loksatta on August 07, 2026.

Financial Performance Highlights

The company’s total income stood at ₹9,517.08 lakh, driven primarily by operational revenue as other income declined sharply to ₹99.23 lakh from ₹616.21 lakh in Q4FY26 and ₹147.63 lakh in Q1FY25. Total expenses increased to ₹10,074.38 lakh from ₹7,566.44 lakh in Q1FY25, outpacing revenue growth and resulting in a pre-tax loss of ₹557.30 lakh.

Standalone figures mirrored the consolidated trend, with a net loss of ₹387.55 lakh compared to ₹169.19 lakh in Q1FY25. Standalone revenue from operations rose 30.3% to ₹9,304.83 lakh. Earnings per share (basic and diluted) stood at ₹(0.75) for consolidated operations and ₹(0.72) for standalone operations, down from ₹(0.38) and ₹(0.35) respectively in the prior year quarter.

What the Numbers Show

A key observation is the significant drop in other income, which fell to ₹99.23 lakh in Q1FY27 from ₹616.21 lakh in the preceding quarter. This reduction contributed to lower total income relative to the revenue growth rate. Additionally, employee benefits expenses rose to ₹1,918.37 lakh from ₹1,461.27 lakh in Q1FY25, indicating increased operational costs that offset the benefits of higher sales volume. The group continues to operate in a single reportable segment: pharmaceuticals.

The paid-up equity share capital increased slightly to ₹5,354.90 lakh from ₹5,350.03 lakh at the end of FY26. The company has seven subsidiaries included in the consolidation, including entities in India, Sharjah, Latvia, Australia, and Dubai.

Zim Laboratories reported a mixed set of Q1 financial results, with revenue showing year-on-year growth but profitability metrics deteriorating significantly over the same period. The company's consolidated net loss widened to 40M rupees from a net loss of 19M rupees in Q1 of the previous year, even as topline performance improved.

Revenue Performance

Zim Laboratories recorded Q1 revenue of 942M rupees, marking a notable increase compared to 717M rupees in the corresponding quarter of the prior year. The year-on-year revenue growth reflects an improvement in the company's topline, though this was insufficient to translate into bottom-line gains during the quarter.

Profitability Under Pressure

Despite the revenue uptick, the company's earnings before interest, taxes, depreciation, and amortisation (EBITDA) declined sharply on a year-on-year basis. EBITDA stood at 25M rupees in Q1, down from 42M rupees in the same quarter last year. The EBITDA margin contracted to 2.6% from 5.9% YoY, indicating that cost escalation outpaced revenue growth during the period.

The following table summarises the key financial metrics for Q1:

Key Takeaways

• Revenue grew to 942M rupees from 717M rupees YoY, reflecting topline improvement.
• EBITDA declined to 25M rupees from 42M rupees YoY, a significant year-on-year drop.
• EBITDA margin contracted by 330 basis points, falling to 2.60% from 5.90% YoY.
• Consolidated net loss widened to 40M rupees compared to a net loss of 19M rupees in the prior year quarter.

Overall, Zim Laboratories' Q1 results highlight a divergence between revenue growth and profitability, with the company's loss position deepening on a year-on-year basis despite higher revenues. The compression in EBITDA margin underscores the cost challenges faced during the quarter.